2015 American Transplant Congress
A Novel, Blocking Anti-CD40 Monoclonal Antibody Prolongs Non-Human Primate Renal Allograft Survival in the Absence of B-Cell Depletion Or Thromboembolic Events
Background. CD40-CD154 pathway blockade prolongs renal allograft survival in non-human primates (NHPs). However, antibodies targeting CD154 were associated with an increased incidence of thromboembolic complications…2015 American Transplant Congress
Germinal Centre Autoimmunity Mediates Progression of Allograft Vasculopathy, With Essential Help Provided By T Follicular Cells
Dept of Surgery, University of Cambridge, Cambridge, United Kingdom.
Introduction: : In our previous work we have shown that donor CD4 T cells within heart grafts initiate anti-nuclear autoantibody responses. Here we clarify the…2015 American Transplant Congress
Distinct Clinical Relevance of BAFF Expression Within the Kidney Graft and Soluble BAFF Serum Levels Indicate Confined Alloimmune Responses Disconnected from the Periphery
As soluble B-cell activating factor (BAFF) serum levels (sBAFF) may not reflect BAFF concentrations within the graft, what could be related to the inconsistencies in…2015 American Transplant Congress
CN Inhibition (But Not mTOR Inhibition) of a Novel CD8+ T Cell Regulatory Mechanism Results in Higher Alloantibody Posttransplant
Department of Surgery, CTC, The Ohio State University Wexner Medical Center, Columbus, OH.
MTOR inhibitors [mTORi; Rapamycin, (Rapa)] and calcineurin inhibitors [CNi; Tacrolimus (Tac)] are immunosuppressive drugs commonly used to suppress the rejection of transplanted organs and tissues.…2015 American Transplant Congress
In Vitro Evidence That CTLA4Ig Attenuates Recall Alloantibody Responses
Background: CTLA4Ig is an agonist that blocks CD28-B7 costimulation, downregulating T cell immunity, but also appears to negate T cell-dependent B cell activation, thus inhibiting…2015 American Transplant Congress
Alterations in Peripheral Blood B Cell Subpopulations in Kidney Transplant Recipients With DSA
Peripheral blood B cell subpopulations were assessed over time (1, 3, 6, 9, and 12 months) in living donor kidney transplant recipients undergoing thymoglobulin (n…2015 American Transplant Congress
Toll-Like Receptor 4-Signaling Abrogates Inhibitory Effect of Calcineurin Inhibitor on B-Cells Responding to Blood Group A-Antigens
Transplant Unit, Hiroshima University, Hiroshima, Japan.
Aim: Bacterial infection following ABO-incompatible organ-transplantation is associated with refractory Ab-mediated rejection. Here, we investigated the influence of toll-like receptor (TLR)-signaling, via the binding of…2015 American Transplant Congress
Molecular Correlates of Atrophy-Fibrosis in Human Kidney Transplants Provides a New Model of Renal Fibrosis
University of Alberta, Edmonton, Canada.
We studied the effect of time post-transplant on atrophy-fibrosis (AF) and the molecular associations with AF in 703 kidney transplant indication biopsies (bx) 3 days…2015 American Transplant Congress
Identification of Mouse Tolerogenic B Cells Expressing PD-L1/PD-L2 in B-1a Subset
Donor lymphocyte infusion (DLI) has been shown to induce donor-specific hyporesponsiveness or even immune-tolerance among alloreactive T cells in different organ transplantation models. However, the…2015 American Transplant Congress
Long Term Outcomes of Tocilizumab Therapy for DSA+ Antibody Mediated Rejection (ABMR) Resistant to IVIG + Rituxan (I+R) Treatment
Intro: Limited options are available for treatment of ABMR in highly-HLA sensitized patients (HS). Treatment options include I+R, PLEX+I+/- R, C5-inhibitor & bortezomib. Approximately 25%…
American Transplant Congress abstracts